Try our Advanced Search for more refined results

Expert Analysis

Issues To Watch In Fed. Circ. Hep C Drug Patent Case

By Robert Scheffel and Matthew Dowd (June 7, 2019, 3:10 PM EDT) -- In a fully briefed appeal scheduled for oral argument on July 9, 2019, the U.S. Court of Appeals for the Federal Circuit will again address the issue of enablement but in an area it rarely wades — the enablement of patent claims directed to a chemical genus defined by chemical structure. The case, Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., may significantly alter patent practice in the chemical arts. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!